Overall, these findings suggest that hyperkalemia entails the underdosing or discontinuation of renin–angiotensin–aldosterone system inhibitors, which is associated with poorer clinical outcomes beyond the potential arrhythmogenic effects [43,47]. The gene discussed is REN; the disease is Hyperkalemia.